Skip to content

NIRF #2 in Pharmacy • 2-Year PG Program

M.S. Pharm. (Pharmacy Practice)

National Institute of Pharmaceutical Education and Research Hyderabad

NIRF Pharmacy Rank

#2

Elite tier among Indian pharma institutes

Key numbers

Program Duration

24 Months

Batch Size

10 Seats

Avg CTC (2025)

₹5.5 LPA

Placement Rate

75%

Investment

2.5L total

~₹1.3L per year

  • 1st Year Tuition1,25,000per year
  • 2nd Year Tuition1,25,000per year

Are you eligible?

  • Academic Background

    B.Pharm or an equivalent pharmacy degree

  • Selection Mode

    Entrance exam-based admission process

Entrance exams

NIPER_JEE

Your 2-Year Journey

  1. Year +0

    Clear NIPER-JEE

    National entrance + interview for just 10 seats

  2. Year +1

    Year 1: Core Clinical Blocks

    Clinical Pharmacy, Pharmacoepidemiology & Hospital Pharmacy Management

  3. Year +2

    Year 2: Practice, Thesis & Placements

    Patient Care, Pharmacoeconomics & recruitment by Apollo, Fortis, Cipla & more

Placement · 2025

Where graduates land

Placement rate

75%

Top recruiters

Apollo HospitalsFortis HealthcareCiplaDr. Reddy's LaboratoriesSun Pharmaceutical
success

Hostel + Scholarships = Less Chaos

NIPER Hyderabad offers on-campus hostel accommodation and scholarship support, so you can focus on clinical rotations instead of hunting for PGs in the city.

The verdict

Worth considering

If you are a B.Pharm grad itching to move beyond bench chemistry into direct patient care and hospital pharmacy leadership, this NIRF #2 program is a rare shot. The tiny 10-seat batch means elite mentoring, and the curriculum is solidly clinical. That said, public placement data is sparse and the entrance is hyper-competitive—definitely talk to current students or alumni before you commit.

Matches what you said

  • NIRF top-tier rank
  • Clinical & hospital pharmacy focus
  • Intimate batch size
  • Hostel & scholarships available

Doesn't match

  • Limited public data transparency
  • Highly competitive entrance (only 10 seats)
  • No AICTE approval
1 / 9